Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03712202
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:09.049768+00:00
Published At
2024-11-06T00:00:00+00:00
Record Updated At
2024-11-06
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Ann Arbor Stage I Hodgkin Lymphoma", "Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma", "Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma", "Ann Arbor Stage IA Hodgkin Lymphoma", "Ann Arbor Stage IB Hodgkin Lymphoma", "Ann Arbor Stage II Hodgkin Lymphoma", "Ann Arbor Stage IIA Hodgkin Lymphoma", "Ann Arbor Stage IIB Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "Lymphocyte-Rich Classic Hodgkin Lymphoma", "Ann Arbor Stage I Lymphocyte-Depleted Classic HL", "Ann Arbor Stage II Lymphocyte-Depleted Classic HL", "Ann Arbor Stage II Mixed Cellularity Classic HL", "Ann Arbor Stage II Nodular Sclerosis Classic HL"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-11-06"
protocolSection.identificationModule.nctId
"NCT03712202"
protocolSection.identificationModule.officialTitle
"A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Ann Arbor Stage I Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IA Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IB Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage II Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IIA Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IIB Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Lymphocyte-Rich Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage I Lymphocyte-Depleted Classic HL (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage II Lymphocyte-Depleted Classic HL (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage II Mixed Cellularity Classic HL (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage II Nodular Sclerosis Classic HL (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.